We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
NeuroBo Pharmaceuticals announced it received written communication from the U.S. Food and Drug Administration (FDA) that the clinical development program for Gemcabene.
Shares in Gemphire Therapeutics more than doubled after its lead drug gemcabene aced a midstage trial in patients with high triglycerides—setting up a phase 3 program.